Back to results
US 2012/0058099 A1Published application
Use of hypoxanthine for promotion of neuronal outgrowth
AssigneeChildren's Medical Center Corporation
InventorCarleen Ann Irwin
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeChildren's Medical Center Corporation
InventorCarleen Ann Irwin
Estimating the term…
Disclosed herein is a method of promoting neuronal outgrowth in a neuron. The method comprises contacting the neuron with an effective amount of hypoxanthine, to thereby promote neuronal outgrowth of the neuron. The hypoxanthine may be contacted in the absence of xanthine oxidase and/or in the absence of exogenous nerve growth factor (NGF), and/or in the absence of exogenous D-mannose, and/or in the absence of exogenous oncomodulin, and/or in the absence of exogenous TGF-B. The neuron may be an optic nerve neuron or a retinal neuron and/or an injured neuron. Neurons may be from the central nervous system (CNS) or the peripheral nervous system (PNS). The methods are useful for treating an injured neuron, for example to an optic nerve neuron, resulting from branch and central vein/artery occlusion, trauma, edema, angle-closure glaucoma, open-angle glaucoma. Methods of treatment of various neurological injuries and diseases, as well as therapeutic compositions, are also disclosed.
A method of promoting neuronal outgrowth in a neuron comprising contacting the neuron with an effective amount of hypoxanthine, to thereby promote neuronal outgrowth of the neuron.
-15. (canceled)
The method of claim 27, wherein the neuronal injury results from a trauma or exposure to a toxin.
(canceled)
(canceled)
-25. (canceled)
The method of claim 27, wherein the neuronal injury is associated with a disease or condition in the subject selected from the group consisting of acute spinal cord damage, stroke, Huntington's disease, Parkinson's disease, Multiple Sclerosis, Alzheimer's disease, multiple system atrophy (MSA), spino-cerebellar atrophy, motor neuronopathy, epilepsy or seizures, peripheral neuropthy, cerebral palsy, glaucoma, macular degeneration, age related macular degeneration, retinitis pigmentosa, retinal detachments, damage associated with laser therapy, and surgical light-induced iatrogenic retinopathy.
A method of treating a neuronal injury in a subject comprising, administering a therapeutically effective amount of hypoxanthine to the subject sufficient to promote neuronal outgrowth in the subject.
(canceled)
(canceled)
A pharmaceutical composition comprising hypoxanthine and a pharmaceutically acceptable carrier.
(canceled)
(canceled)
Dependencies are inferred from the claim text.